Clinical Trials

UK drug discovery market ‘thriving’ says new report

27 May 2019 | By Drug Target Review

A new report reveals a thriving service and supply sector for the UK in addition to its research and development biotechs.

Update on the development of new novel cancer immunotherapy

24 May 2019 | By Drug Target Review

The SCIB2 vaccine is to to be administered using new nanoparticle formulation in planned Phase 1/2 clinical trial.

New method could speed up drug development and diminish drug trial fails

21 May 2019 | By Drug Target Review

A new method of assessing the actions of medicines by matching them to their unique protein receptors could accelerate drug development.

Genomic analysis identifies potential prostate cancer targets

14 May 2019 | By Drug Target Review

In a recent study more than half of patients with advanced prostate cancers appear to be strong candidates for targeted cancer therapies.

WINTHER trial yields promising results

2 May 2019 | By Drug Target Review

Comprehensive tumour profiling promises new therapeutic options for patients with advanced cancer.

Webinar highlights: Integrated fragment based approach reveals enzymatic inhibitors with potential therapeutic application

10 December 2018 | By NanoTemper Technologies

This webinar, held on 25 October 2018, presented the results from integrated fragment-based approaches for Indoleamine 2,3 dioxygenase 1 (IDO1), an enzyme widely recognised as a drug target for the development of immunotherapeutic small molecules in oncology, unveiling the first ligands able to modulate non-catalytic signalling.

Webinar highlights: Recent advances in diagnostics and treatments – from small molecules to cellular therapies

7 December 2018 | By Bio-Techne

The webinar presented an overview of the pre-clinical milestones, the current status of the global drug pipeline and a description of a number of novel drugs undergoing clinical trials.

T-cells engineered to recognise tumours expressing the CD30 protein marker

4 December 2018 | By Drug Target Review

Researchers have genetically engineered immune cells to recognise and fight Hodgkin and non-Hodgkin lymphoma cells...

Integrated fragment-based approach reveals enzymatic inhibitors with potential therapeutic application

25 October 2018 | By NanoTemper Technologies

In this webinar, speakers presented results of integrated fragment-based approaches that have led to the discovery of the first ligands of IDO1 that are able to modulate non-catalytic signalling functions of the enzyme...

Cancer vaccine shows promise for HER2-positive cancers

1 October 2018 | By Drug Target Review

Treatment with a HER2-targeted therapeutic cancer vaccine provided clinical benefit to several patients with metastatic HER2-positive cancers...

Kidney disease biomarker could help detect COPD

28 September 2018 | By Iqra Farooq (Drug Target Review)

A biomarker usually used with kidney disease, could potentially be used to detect COPD through identifying levels of albuminuria in urine...

Agilent Technologies

Amyloid beta – a good therapeutic target?

19 September 2018 | By Iqra Farooq (Drug Target Review)

Phase III clinical trials for a drug targeting amyloid beta plaques are underway, with results expected in the next two to three years...

Carving a pathway toward personalised cancer therapy

11 September 2018 | By Drug Target Review

Individualised therapies that target the specific genetic features of tumours have the potential to transform cancer diagnosis, treatment and care. However, several challenges remain before these approaches can be widely used in the clinic.

CBD improves survival rates of mice with pancreatic cancer

31 July 2018 | By Dr Zara Kassam (Drug Target Review)

Mice with pancreatic cancer that were treated with CBD alongside chemotherapy, survived almost three times longer than those treated with chemotherapy alone...